Insulin medicines: Supply chain
Output and value
World output and its value, with year and source
| Measure | Value | Unit | Year | Source |
|---|---|---|---|---|
| Novo Nordisk sales of insulin (one company's sales, not world output) | 53,137 | DKK million | 2025 | [12] |
| Sanofi net sales of Lantus (insulin glargine; one company's sales; table value, Appendix 1 net sales table) | 1733 | EUR million | 2025 | [13] |
| Sanofi net sales of Toujeo (insulin glargine; one company's sales; table value, Appendix 1 net sales table) | 1345 | EUR million | 2025 | [13] |
as of 2026-11-13
Where it is made
Country shares of world output
| Country | Measure | Year | Source |
|---|---|---|---|
| India | A press report says Wockhardt sells human insulin in India and exports it to around ten countries, and Biocon, Eris and Lupin sell lower-cost glargine in India; no country shares of world output were found | 2026 | [10] |
| Malaysia | Biocon has invested $600 million since 2011 in its Johor plant, as reported | 2026 | [10] |
as of 2026-11-13
Main companies
The largest makers and their shares
| Company | Country | Share | Measure | Year | Source |
|---|---|---|---|---|---|
| Novo Nordisk | Denmark | – | Insulin sales of DKK 53,137 million in 2025 (one company's sales); headquarters in Bagsværd, Denmark | 2025 | [12] |
| Sanofi | France | – | Lantus €1,733 million and Toujeo €1,345 million net sales in 2025 (table values); global headquarters in Paris | 2025 | [13][19] |
| Eli Lilly and Company | United States of America | – | Began selling Iletin in 1923, in Indianapolis, Indiana; no insulin sales figure found in a source opened | 1923 | [3][4] |
| Eris Lifesciences | India | 24 | Share of India's regular human insulin cartridge market, up from 13% over FY26, as Eris told investors (the company's own figure, reported in the press; one segment); registered office in Ahmedabad | 2026 | [10][20] |
as of 2026-11-13
Supply chains of the main makers
For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ
| Country | Inputs from | Makers | How variants differ | Year | Source |
|---|---|---|---|---|---|
| India | Not stated in the pages opened | Biocon, Eris and Lupin (lower-cost glargine); Wockhardt (human insulin, exported to about ten countries); Novo Nordisk, which a press report says told its marketing partner Abbott India that human insulin in Penfill cartridges and FlexPen devices would be withdrawn once stock ran out; Sanofi's Lantus remains the reference basal insulin | Human insulin such as Human Mixtard is under price control, the report says; the once-weekly analogue Awiqli is on sale | 2026 | [10] |
as of 2026-11-13
Industries that make it
The industries and kinds of firm that make it
Made by- Innovator pharma and biotech companies World Three multinational companies control more than 90% of the insulin market, WHO said in 2021 [1]; Novo Nordisk and Sanofi sales are in [12][13].
- Finished-dose formulators (branded and generic) India A press report says Biocon, Eris and Lupin sell lower-cost glargine in India and Wockhardt sells human insulin [10].
as of 2026-11-13
Rules and standards
Labels, efficiency and emission standards, producer responsibility, bans and tariffs
| Rule | Place | Year | What it does | Source |
|---|---|---|---|---|
| NPPA ceiling prices for human insulin injections (price fixation orders S.O. 2734(E) and 2735(E)) | India | 2012 | Government review orders confirm that the NPPA orders of 16 November 2012 fixed ceiling prices for human insulin injections [18]; a press report says the ceiling applied irrespective of brand, with separate ceilings for domestic and imported insulin, and that Biocon and Wockhardt objected to the higher ceiling for imports [11] | [18][11] |
| Price control on human insulin, such as Human Mixtard | India | 2026 | A 2026 press report says Human Mixtard sits under price control and earns close to Rs 800 crore a year | [10] |
| WHO prequalification of human insulin (pilot procedure) | World | 2022 | WHO prequalified the first human insulins on 28 September 2022; full assessment includes WHO inspection of the relevant manufacturing facilities | [7][8] |
as of 2026-11-13
India
India's output, trade, makers and rules in a short paragraph
About 6 million people in India were on insulin therapy in 2026, a press report says [10]. Biocon, Eris and Lupin sell lower-cost glargine and Wockhardt sells human insulin; the report says Novo Nordisk is withdrawing human insulin in Penfill cartridges and FlexPen devices [10]. NPPA orders of November 2012 fixed ceiling prices for human insulin injections [18][11], and Human Mixtard is under price control [10]. No source opened gives India's output, trade or import share.
as of 2026-11-13
Trade
World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)
| Flow | Value | Unit | Volume | Unit | Year | Source |
|---|---|---|---|---|---|---|
| World exports | 5.28 | USD billion | 23.3 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Average export value (calculated) | 226.9 | USD per kg | – | – | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: Germany (40.9% of world exports) | 2.16 | USD billion | 1.5 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: France (29.3% of world exports) | 1.55 | USD billion | 7.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: United States (9.8% of world exports) | 0.52 | USD billion | 1.4 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: India (2.8% of world exports) | 0.15 | USD billion | 2.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Exporter: Hungary (2.1% of world exports) | 0.11 | USD billion | 0.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| India exports (rank 4, 2.8% of world) | 0.15 | USD billion | 2.6 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| India imports (rank 7, 2.9% of world) | 0.19 | USD billion | 0.9 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: United States (14.8% of world imports) | 0.95 | USD billion | 5.2 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: Germany (12.3% of world imports) | 0.79 | USD billion | 1.8 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
| Importer: France (6.5% of world imports) | 0.42 | USD billion | 1.9 | thousand tonnes | 2024 | UN Comtrade, HS 3004.31 |
Worked out from data
Sources
- New WHO report maps barriers to insulin availability and suggests actions to promote universal access World Health Organization, 2021, news item of 12 November 2021
- Insulin Development and Commercialization American Chemical Society (National Historic Chemical Landmark), 2023, landmark booklet, © 2023 American Chemical Society
- Manufactured insulin, 'Iletin', United States, 1923 | Science Museum Group Collection Science Museum Group, object record co143500
- First human insulins prequalified World Health Organization, Prequalification of Medical Products, 2022, news item of 28 September 2022
- Human Insulin | WHO - Prequalification of Medical Products World Health Organization, Prequalification of Medical Products, prequalification page for human insulin; the page shows no start date for the pilot
- India 2030: Who Supplies the Next 10 Million? BioSpectrum India (Ankit Kankar), 2026, article of 1 November 2026
- 1 insulin price cap for all brands Business Standard (Sushmi Dey), 2012, article of 21 November 2012
- Financial performance - Novo Nordisk Annual Report 2025 Novo Nordisk, 2025, insulin sales sentence; page footer gives Novo Nordisk HQ, Novo Alle 1, 2880 Bagsværd, Denmark
- 2025: strong sales and EPS growth. Sanofi, 2026, full-year 2025 results press release, Paris, January 29, 2026; Appendix 1, FY 2025 net sales table
- Review orders on the review applications of M/s Eli Lilly & Co. (India) Pvt. Ltd. against NPPA price fixation orders for insulin (File No. 31015/17/2012-PI.I and others) Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, 2013, order of 15 January 2013 on S.O. 2734(E) and 2735(E); the document gives no price amounts
- Press Release: Sanofi moves into its new Paris global headquarters Sanofi, 2022, press release of 28 November 2022
- Outcome of the board meeting held today, i.e., Wednesday, November 12, 2025 Eris Lifesciences Limited (filing to the National Stock Exchange of India), 2025, letterhead: Registered & Corporate Office, Bodakdev, Ahmedabad